Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701988 | 0.85 | EPHX2 (0.48) | MEN1KMT2AALDH1A1EPHX2SPR | |
| SCHEMBL18711914 | 0.79 | L3MBTL1 (0.61) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL18711907 | 0.78 | PKM (0.66) | MEN1KMT2AALDH1A1EPHX2SPR | |
| SCHEMBL18711451 | 0.72 | KMT2A (0.77) | MEN1KMT2AALDH1A1GAAPOLB | |
| SCHEMBL18711517 | 0.72 | PKM (0.73) | KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL18711334 | 0.72 | ALDH1A1 (0.75) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL18711516 | 0.71 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1MAPTCNR1 | |
| SCHEMBL18711450 | 0.71 | CNR1 (0.68) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL1940087 | 0.70 | HTT (0.46) | MEN1KMT2AEPHX2MAPTPOLB | |
| SCHEMBL1939095 | 0.70 | L3MBTL1 (0.51) | MEN1KMT2AALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | MEN1 4876/4885KMT2A 2884/4885ALDH1A1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.